Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2003
06/24/2003US6583299 α-amino-β-sulfonyl hydroxamic acid compounds
06/24/2003US6583265 Cyclosporins
06/24/2003US6583219 Three-dimensional, crosslinked interpenetrating polymer network
06/24/2003US6583182 Atomic numbers 21-30 are components of enzymes required for nucleic acid replication; substituted polyaza compounds inhibit cell replication by decreaseing bioavailability of iron or copper
06/24/2003US6583159 Substitute 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use
06/24/2003US6583154 Compounds and methods which modulate feeding behavior and related diseases
06/24/2003US6583146 Thiazolopyrimidine compounds, its production and use
06/24/2003US6583143 CRF receptor antagonists and methods relating thereto
06/24/2003US6583141 T cell mediated rheumatic diseases
06/24/2003US6583137 Protease inhibitors
06/24/2003US6583134 Aza- indolyl derivatives for treating obesity
06/24/2003US6583128 Immunoregulatory compounds and derivatives and methods of treating diseases therewith
06/24/2003US6583127 Administering phosphatides such as 1-O-octadecyl-2-O-methyl glycero-3-phosphocholine, enantiomers and/or stereisomers as antiinflammatory agents for prophylaxis of inflammatory bowel disease, gastrointestinal or respiratory system disorders
06/24/2003US6583123 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
06/24/2003US6583118 Chondroprotective agents
06/24/2003US6583108 Human bikunin
06/24/2003US6582747 Dry cocoa mix containing a mixture of non-alkalized and alkalized cocoa solids
06/24/2003US6582718 Topical, ophthalmic cyclosporin A formulation having better distribution due to surfactant (polyoxyethylene fatty acid esters) causing less irritation to the eyes
06/24/2003US6581773 Weight-specific elixir dosage calculator
06/19/2003WO2003050295A2 Assays and implements for determining and modulating hsp90 binding activity
06/19/2003WO2003050251A2 Hematopoietic cells from human embryonic stem cells
06/19/2003WO2003050128A1 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
06/19/2003WO2003050123A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
06/19/2003WO2003050101A1 Deuterated substituted dihydrofuranones and medicaments containing these compounds
06/19/2003WO2003050095A1 Substituted benzoxazoles and analogues as estrogenic agents
06/19/2003WO2003050091A1 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
06/19/2003WO2003050067A2 Vitamin d analogues
06/19/2003WO2003050066A1 Functionalized higher diamondoids
06/19/2003WO2003049772A2 Guanidinium transport reagents and conjugates
06/19/2003WO2003049752A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
06/19/2003WO2003049742A1 Method for administering birb 796 bs
06/19/2003WO2003049739A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003WO2003049738A1 Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
06/19/2003WO2003049733A1 High-concentration stable meloxicam solutions for needle-less injection
06/19/2003WO2003049730A1 Treatment of statin side effects using uridine derivatives
06/19/2003WO2003049725A2 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases
06/19/2003WO2003049723A2 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
06/19/2003WO2003049721A1 Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
06/19/2003WO2003049702A2 Vanilloid receptor ligands and their use in treatments
06/19/2003WO2003049698A2 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003WO2003049679A2 Mitotic kinesin inhibitors
06/19/2003WO2003013436A3 Kavalactone compositions and methods of use
06/19/2003WO2003009777A3 Delivery of therapeutic capable agents
06/19/2003WO2003005960A3 Novel bicyclic and tricyclic cannabinoids
06/19/2003WO2002060434A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
06/19/2003WO2002051429A3 Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages
06/19/2003WO2002044342A9 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
06/19/2003WO2002034899A3 Tec kinase assay
06/19/2003WO2002022153A3 Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
06/19/2003US20030114683 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors
06/19/2003US20030114668 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
06/19/2003US20030114646 Human cystatin F
06/19/2003US20030114529 HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation
06/19/2003US20030114527 Administering an immediate release tablets containing 400 mg of 5-methyl-2-(2'- chloro-6'-fluoroanilino)phenylacetic acid or salts to a patient for the treatment of cyclooxygenase-2 mediated diseases
06/19/2003US20030114509 Prophylactic or therapeutic drug for renal diseases
06/19/2003US20030114505 Novel isoxazole and thiazole compounds and use thereof as drugs
06/19/2003US20030114478 Asthma therapy; antiinflammatory agents
06/19/2003US20030114473 Anticancer agents
06/19/2003US20030114464 Synergistic mixture containing quinolone antibiotic such as floxacin; also fungicide; topical applying to eye
06/19/2003US20030114462 Drug abruse, alcoholism; respiratory system disorders, cardiovascular disorders
06/19/2003US20030114460 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/19/2003US20030114456 Antiinflammatory agents, analgesics, antipyretics
06/19/2003US20030114449 Saccharin derivatives as orally active elastase inhibitors
06/19/2003US20030114434 Extended duration light activated cancer therapy
06/19/2003US20030114432 Antiinflammatory agents; rheumatic diseases; anticancer agents
06/19/2003US20030114428 Pharmaceutical compositions for the treatment of asthma
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114418 Analgesics; antiinflammatory and arthritic agents; osteoarthritis; rheumatic diseases; gastrointestinal, nervous system, respiratory disorders; wound healing agents; vision defects; kits
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030113881 D-enzyme compositions and methods of their use
06/19/2003US20030113867 Muscle receptor proteins; transport proteins; antitumor agents; antiinflammatory agents; antidiabetic agents; modulation of muscle contraction
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113775 7118, a human arginine N-methyltransferase family member and uses therefor
06/19/2003US20030113763 Oligonucleotide compositions and their use to induce apoptosis
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113392 Proteoglycan compositions for treating arthritic inflammatory conduitions
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113333 A kit containing a binding protein and a carrier molecule, binds with a hapten moiety and binds with a target antigen; monoclonal antibodies and engineered antibodies
06/19/2003US20030113331 An antagonist specifically binds to a denatured collagens; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
06/19/2003US20030113323 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity
06/19/2003US20030113306 Probiotic lactobacillus casei strains
06/19/2003US20030113295 Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
06/19/2003US20030113278 Treatment of excessive radiation (e.g. sunburn) exposure
06/19/2003US20030113262 Gpib-lipid bond construct and use thereof
06/19/2003CA2471743A1 Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds
06/19/2003CA2469858A1 Functionalized higher diamondoids
06/19/2003CA2469709A1 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003CA2469607A1 Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
06/19/2003CA2469588A1 Highly concentrated stable meloxicam solutions for needleless injection
06/19/2003CA2469519A1 Deuterated substituted dihydrofuranones and medicaments containing these compounds
06/19/2003CA2469483A1 Hematopoietic cells from human embryonic stem cells
06/19/2003CA2469336A1 Guanidinium transport reagents and conjugates
06/19/2003CA2469316A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2468544A1 Vanilloid receptor ligands
06/19/2003CA2468202A1 Assays and implements for determining and modulating hsp90 binding activity
06/19/2003CA2468156A1 Azolopyrimidinone compounds and their use
06/19/2003CA2465759A1 Method for administering birb 796 bs
06/18/2003EP1319709A1 Disruption of the glutathione S-transferase-omega-1 gene
06/18/2003EP1319184A2 Use of antibodies against specific mhc-peptide complexes
1 ... 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 ... 1272